Rachel Lenington
2021
In 2021, Rachel Lenington earned a total compensation of $2.6M as Chief Operating Officer at Athira Pharma.
Compensation breakdown
| Non-Equity Incentive Plan | $110,640 |
|---|---|
| Option Awards | $1,754,205 |
| Salary | $230,500 |
| Stock Awards | $460,200 |
| Other | $33 |
| Total | $2,555,578 |
Lenington received $1.8M in option awards, accounting for 69% of the total pay in 2021.
Lenington also received $110.6K in non-equity incentive plan, $230.5K in salary, $460.2K in stock awards and $33 in other compensation.
Rankings
In 2021, Rachel Lenington's compensation ranked 5,063rd out of 12,415 executives tracked by ExecPay. In other words, Lenington earned more than 59.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,063 out of 12,415 | 59th |
Division Manufacturing | 2,132 out of 5,505 | 61st |
Major group Chemicals And Allied Products | 914 out of 2,375 | 62nd |
Industry group Drugs | 818 out of 2,096 | 61st |
Industry Biological Products, Except Diagnostic Substances | 204 out of 449 | 55th |
Source: SEC filing on April 5, 2023.
Lenington's colleagues
We found two more compensation records of executives who worked with Rachel Lenington at Athira Pharma in 2021.